PARTNER FEATURE ▶▶▶
subtype H1avN1 is expected to also protect against H1avN2, provided the H1 proteins of the two viruses are (almost) identical. In contrast, an H1N1 vaccine may be useless against circulat- ing H1N1 viruses if the H proteins differ significantly in the im- munogenic regions important for the binding of neutralising antibodies. Recent studies on human influenza viruses now suggest that immunity against the neuraminidase component also plays a substantial accessory role in conveying protection. The majority of human influenza vaccines are entirely com- posed of haemagglutinin and neuraminidase proteins, the major viral determinants that induce protective immunity. Other viral proteins also induce immunity that may be help- ful in overcoming infection. The veterinary vaccines licensed in Europe do contain full virus preparations, including all structural viral proteins. Any strategy that aids in enhancing and broadening vaccine efficacy and induces protection against a wide range of IAV variants is highly welcome. Prime-boost concepts may act in this direction. Another option, which has been implemented in the licensed SIV vaccines in Europe, is the use of adjuvants in the vaccine composition which specifically stimulate the immune system and may potentiate vaccine efficacy.
New influenza G4 variant in China To close, a few words on the new G4 variant that Chinese re- searchers have reported on. The epidemiology of SIV in Asia has been even more complicated compared to Europe be- cause not only Eurasian but also North American SIV strains and reassortants thereof are detected. The recently reported G4 genotype belongs to the H1av subtype and seems to have gained some primacy among SIVs in China. That strain was re- ported to have zoonotic properties that make it a pre-pan- demic candidate. However, human infections, confirmed by virus detection, were detected only sporadically and there was no evidence for sustained human-to-human transmission chains. As such, this situation does not differ qualitatively from the European status reported in the study on European herds.
*The author of the article was one of the main authors of the scientific study. He is attached to the Institute of Diagnostic Virology (IVD), Federal Research Institute for Animal Health, Germany, and is extraordinary professor at the Institute of Infec- tion Medicine, Christian-Albrechts-University, Kiel, Germany.
Authors of Ceva Animal Health were involved in the scientific publication.
UNLEASH THE POWER OF CLEANING AND DISINFECTING
Virocid®
THE GREATEST DISINFECTANT FOR A REASON!
Keno™ san
THE STANDARD IN CLEANING!
www.cidlines.com 12 ▶PIG PROGRESS | Volume 36, No. 7, 2020
Use biocides with precaution. Before any use, read the label and the information concerning the product. This product is not necessary available or registered in every country. ff
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36
